FDA/CDC

FDA advisory committee recommends volanesorsen for rare triglyceride disorder


 

REPORTING FROM an fda advisory committee meeting

The FDA is expected to decide on the application by August 30. The FDA usually follows the recommendations of its advisory panels, which are not binding.


ilacy@mdedge.com

Pages

Recommended Reading

Statins, ACE inhibitors linked to fetal cardiac anomalies
MDedge Endocrinology
Cardiovascular risk in type 2 diabetes: Patients are often clueless
MDedge Endocrinology
Life and health are not even across the U.S.
MDedge Endocrinology
VIDEO: Meta-analysis: Mortality, safety data may favor SGLT2 inhibitors in T2DM
MDedge Endocrinology
‘Fast food swamps’ linked to type 1 diabetes
MDedge Endocrinology
Targeting obesity could slow brain aging in psychosis
MDedge Endocrinology
CVD risk high in individuals who once had metabolically healthy obesity
MDedge Endocrinology
Sucralose sparks appetite in obese, not lean, individuals
MDedge Endocrinology
MI before age 50? Think familial hypercholesterolemia, substance abuse
MDedge Endocrinology
Metabolic syndrome scoring system predicts CVD in type 2 diabetes
MDedge Endocrinology